529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors
oleh: Rebecca Kristeleit, Howard Burris, Kristen Spencer, Sarina Piha-Paul, Hans Prenen, Tara Mitchell, David Pinato, Solmaz Sahebjam, Donna Graham, Nuria Kotecki, Eric Van Cutsem, Brant Delafontaine, Thomas Karasic, Jeannie Daniel, Kevin O’Hayer, Ryan Geschwindt
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2021-11-01 |
Deskripsi
No description available for this item.